BNP Paribas Financial Markets Grows Stock Position in Ultragenyx Pharmaceutical Inc. $RARE

BNP Paribas Financial Markets raised its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 57.6% during the fourth quarter, Holdings Channel reports. The institutional investor owned 903,050 shares of the biopharmaceutical company’s stock after buying an additional 330,031 shares during the period. BNP Paribas Financial Markets’ holdings in Ultragenyx Pharmaceutical were worth $20,770,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. raised its holdings in Ultragenyx Pharmaceutical by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 10,263,815 shares of the biopharmaceutical company’s stock worth $236,068,000 after purchasing an additional 131,087 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its stake in shares of Ultragenyx Pharmaceutical by 614.1% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company’s stock valued at $65,205,000 after buying an additional 1,864,164 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Ultragenyx Pharmaceutical by 3.9% during the 3rd quarter. Wellington Management Group LLP now owns 1,945,129 shares of the biopharmaceutical company’s stock valued at $58,509,000 after acquiring an additional 73,309 shares in the last quarter. Geode Capital Management LLC increased its stake in Ultragenyx Pharmaceutical by 16.3% during the 4th quarter. Geode Capital Management LLC now owns 1,838,208 shares of the biopharmaceutical company’s stock worth $42,287,000 after buying an additional 257,701 shares during the period. Finally, Aberdeen Group plc grew its holdings in Ultragenyx Pharmaceutical by 51.0% during the 4th quarter. Aberdeen Group plc now owns 1,469,951 shares of the biopharmaceutical company’s stock worth $33,809,000 after acquiring an additional 496,295 shares in the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, Director Shehnaaz Suliman sold 5,740 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $25.12, for a total value of $144,188.80. Following the transaction, the director directly owned 27,951 shares of the company’s stock, valued at approximately $702,129.12. The trade was a 17.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Howard Horn sold 4,683 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $24.90, for a total value of $116,606.70. Following the completion of the transaction, the chief financial officer directly owned 110,342 shares in the company, valued at approximately $2,747,515.80. This trade represents a 4.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 20,103 shares of company stock worth $478,186. Insiders own 5.20% of the company’s stock.

Ultragenyx Pharmaceutical Trading Down 6.0%

RARE stock opened at $21.91 on Friday. The stock has a market capitalization of $2.16 billion, a P/E ratio of -3.59 and a beta of 0.37. Ultragenyx Pharmaceutical Inc. has a 12 month low of $18.29 and a 12 month high of $42.37. The firm has a 50-day moving average price of $23.69 and a 200-day moving average price of $25.46.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.49) by ($0.35). Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 1,024.42%. The firm had revenue of $136.00 million during the quarter, compared to analyst estimates of $158.19 million. During the same period in the prior year, the company earned ($1.57) EPS. The business’s quarterly revenue was down 2.2% compared to the same quarter last year. As a group, equities analysts predict that Ultragenyx Pharmaceutical Inc. will post -4.57 EPS for the current fiscal year.

Analysts Set New Price Targets

RARE has been the topic of a number of analyst reports. Guggenheim dropped their price objective on shares of Ultragenyx Pharmaceutical from $52.00 to $43.00 and set a “buy” rating on the stock in a report on Friday, May 8th. Morgan Stanley raised their price objective on Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the company an “overweight” rating in a research note on Thursday, April 16th. Cantor Fitzgerald raised their target price on Ultragenyx Pharmaceutical from $84.00 to $96.00 and gave the company an “overweight” rating in a report on Thursday, May 21st. Barclays dropped their target price on Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating for the company in a report on Wednesday, April 29th. Finally, Wall Street Zen raised shares of Ultragenyx Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Ultragenyx Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average target price of $59.56.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.